/XBIO
XBIO Stock - Xenetic Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$2.15+4.37%
+$0.09 (+4.37%) • Dec 19
41
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.24
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.37
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.13 – $2.17
TARGET (TP)$2.47
STOP LOSS$1.98
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.41
52W High$13.93
52W Low$1.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.50M | $2.54M | $1.71M | $1.16M | $436,942 |
| Gross Profit | $2.50M | $2.54M | $1.71M | $1.16M | $436,942 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-4,204,428 | $-4,515,715 | $-6,717,908 | $-5,746,765 | $-13,937,663 |
| Net Income | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 | $-10,893,466 |
| Net Margin | -158.4% | -162.8% | -383.9% | -486.4% | -2493.1% |
| EPS | $-2.57 | $-2.71 | $-4.49 | $-5.39 | $-17.04 |
Company Overview
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XBIOBeat Rate
56%
Last 18 quarters
Avg Surprise
-51.2%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q1 24
+11.5%
$-0.77vs$-0.87
Q2 24
+1.3%
$-0.78vs$-0.79
Q3 24
0.0%
$-0.83vs$-0.83
Q4 24
-100.0%
$-0.28vs$-0.14
Q2 25
No data
Q2 25
+18.1%
$-0.59vs$-0.72
Q3 25
+29.7%
$-0.45vs$-0.64
Q4 25
+32.7%
$-0.33vs$-0.49
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.49 | $-0.33 | +32.7% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.64 | $-0.45 | +29.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.72 | $-0.59 | +18.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | — | $-0.68 | — | — |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.28 | -100.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.83 | $-0.83 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $-0.79 | $-0.78 | +1.3% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.87 | $-0.77 | +11.5% | ✓ BEAT |
Q4 2023 | Nov 10, 2023 | $-1.12 | $-0.69 | +38.4% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-1.13 | $-0.69 | +38.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.10 | $-0.60 | +45.5% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.09 | $-1.00 | -1011.1% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1.80 | $-0.60 | +66.7% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-1.20 | $-1.90 | -58.3% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.10 | $-1.20 | -9.1% | ✗ MISS |
Q1 2022 | Mar 22, 2022 | $-1.50 | $-1.80 | -20.1% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-1.20 | $-1.30 | -8.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-1.60 | $-1.30 | +18.8% | ✓ BEAT |
Q2 2021 | May 12, 2021 | $-1.30 | $-1.50 | -15.4% | ✗ MISS |
Latest News
Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies
📈 PositiveBenzinga•Nov 19, 2025, 01:47 PM
Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate
📈 PositiveBenzinga•Nov 13, 2025, 01:49 PM
Xenetic Biosciences shares are trading lower after the company announced the pricing of a $4.5 million offering of 735,000 shares at $6.12 per share.
📉 NegativeBenzinga•Oct 10, 2025, 01:35 PM
Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M
➖ NeutralBenzinga•Oct 10, 2025, 01:33 PM
Frequently Asked Questions about XBIO
What is XBIO's current stock price?
Xenetic Biosciences, Inc. (XBIO) is currently trading at $2.15 per share. The stock has moved +4.37% today.
What is the analyst price target for XBIO?
No analyst price targets are currently available for this stock.
What sector is Xenetic Biosciences, Inc. in?
Xenetic Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XBIO's market cap?
Xenetic Biosciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does XBIO pay dividends?
No, Xenetic Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABP
Abpro Corporation
$5.06
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
KALA
KALA BIO, Inc.
$0.62
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.88
Mkt Cap: $0.0B
QLGN
Qualigen Therapeutics, Inc.
$3.21
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
Explore stocks similar to XBIO for comparison